Monitoring and treatment of minimal residual cancer of the prostate

G. Mathe, A. V. Schally, A. M. Comaru-Schally, R. Y. Mauvernay, M. L. Vovan, D. Machover, J. L. Misset, B. Court, P. Bouchard, J. Duchier, P. Morin, R. Keiling, P. Kerbrat, E. Achille, J. C. Tronc, J. P. Fendler, E. Papo, R. Metz, G. Prevot

Research output: Contribution to journalArticlepeer-review

Abstract

In manifest prostatic carcinoma, partial and complete remissions are obtained in 14-44% of patients as judged by different sets of criteria, but in up to 61% as judged by a decrease in prostatic acid phosphatase. Moreover, this decrease is poorly correlated to that of prostatic size. Prostatic acid phosphatase is therefore considered to be a relatively non-specific tumor marker. A complete remission, i.e. a stage of minimal residual disease, is obtained in about 25% of the patients. Continued endocrine treatment involves the risk of a flare-up of the disease, which is probably small. Additionally, in minimal residual disease, prolonged maintenance treatment requires minimizatio of side effects. D-Trp-6-LH-RH appears to lead to less gynecomastia and thromboembolism than some other forms of adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)65-74
Number of pages10
JournalMedical Oncology and Tumor Pharmacotherapy
Volume5
Issue numberSUPPL. 1
StatePublished - 1988
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Monitoring and treatment of minimal residual cancer of the prostate'. Together they form a unique fingerprint.

Cite this